CMS Acquires Wuhan YZY Biopharma’s Bispecific Antibody Assets for Fundus Disease
China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY...
Company
HitGen and LoQus23 Therapeutics Partner on DNA Encoded Library for Neurodegeneration
China-based HitGen Inc. (SHA: 688222) announced a strategic partnership with UK-headquartered LoQus23 Therapeutics Ltd, leveraging...
Roche Diagnostics and Topgen Biopharm Launch Innovation Center in Chongqing
Swiss diagnostics giant Roche Diagnostics and China-based Topgen Biopharm announced the establishment of a strategic...
Hybio Pharmaceutical Signs Tech Transfer Deal with China’s CDC for COVID-19 Vaccine Peptide Sequences
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that it has signed a technology transfer...
Yunnan Baiyao and Huawei Partner on AI-Driven Drug Development
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a Kunming-based pharmaceutical firm, has entered into a...
Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...
Sichuan Kelun Pharmaceutical and Merck Sharp & Dohme Corp. Ink Second ADC Licensing Deal
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that US-based Merck Sharp & Dohme...
SinoPharm CNBG’s F61 Monoclonal Antibody Receives NMPA Clinical Trial Approval
SinoPharm CNBG Wuhan Institute of Biological Products Co., Ltd’s F61, a recombinant broad-spectrum novel coronavirus...
Legend Biotech Plans USD 250M Secondary Offering to Fund CAR-T Therapy Development
China-based Legend Biotech Corporation (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T cell...
AbbVie’s Allergan Aesthetics CoolAdvantage Applicator Wins NMPA Approval
US-based AbbVie’s Allergan Aesthetics announced that it has received marketing approval from the National Medical...
Henlius Biotech’s Hanquyou Approved in Australia for HER2-Positive Cancers
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received marketing approval from Australia’s...
Hengrui Medicine’s SHR-1802 + SHR-1316 Combo Receives NMPA Approval for Solid Tumor Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Betta Pharmaceuticals Enrolls First Patient in BPI-442096 Phase I Study for Solid Tumors
China-based Betta Pharmaceuticals (SHE: 300558) announced that the first subject has been enrolled in a...
Hengrui Medicine’s SHR-A1811 Combo Receives NMPA Approval for HER2+ NSCLC Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Ascentage Pharma Launches Olverembatinib Named Patient Program with Tanner Pharma
China-based Ascentage Pharma (HKG: 6855) announced the launch of a Named Patient Program (NPP) for...
GenFleet Therapeutics’ GFH018 Receives CTA Approval for Two Clinical Trials in China
Shanghai-based biotech company GenFleet Therapeutics announced that two clinical trial applications (CTAs) for its drug...
NMPA Approves Genuine Biotech’s Azvudine for COVID-19, Fosun Pharma Inks Licensing Deal
China’s National Medical Products Administration (NMPA) has conditionally approved HeNan Genuine Biotech Co., Ltd’s azvudine...
3D Medicines Files IPO Prospectus for Hong Kong Listing
China-based oncology specialist 3D Medicines has published its initial public offering (IPO) prospectus with the...
I-Mab Doses First Patient in Global Phase I Study for TJ-CD4B in Solid Tumors
I-Mab (NASDAQ: IMAB), a Nasdaq-listed company since 2020, announced that the first patient has been...
Rona Therapeutics Licenses Sanofi’s siRNA Platform for Global Development
Shanghai-based RNA therapeutics specialist Rona Therapeutics has entered into a licensing agreement with French pharmaceutical...